SCHEMBL5546049

SCHEMBL5546049

O=COC(c1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.50
TDO2 P48775 3/20 0.50
HSD17B10 Q99714 1/20 0.41
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 3/20 0.39
HIF1A Q16665 3/20 0.39
MAPK1 P28482 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.38
ADRB2 P07550 1/20 0.38
POLB P06746 1/20 0.37
CYP2A6 P11509 1/20 0.36
BRD4 O60885 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
FFAR2 O15552 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537752 0.92 IDO1 (0.58) IDO1TDO2LMNASMN1; SMN2TSHR
SCHEMBL5545262 0.87 IDO1 (0.46) IDO1TDO2LMNASMN1; SMN2TP53
SCHEMBL5545323 0.86 IDO1 (0.43) IDO1TDO2TSHRHIF1ADRD3
SCHEMBL14628340 0.78 ADRB2 (0.45) IDO1TDO2HSD17B10LMNATSHR
SCHEMBL5545007 0.77 IDO1 (0.41) IDO1TDO2TSHR
SCHEMBL5545230 0.77 IDO1 (0.52) IDO1TDO2SLC6A3
SCHEMBL5542504 0.77 IDO1 (0.47) IDO1TDO2LMNASMN1; SMN2MAPK1
SCHEMBL858 0.76 CYP2D6 (0.42) IDO1TDO2LMNASMN1; SMN2TSHR
SCHEMBL5544365 0.75 ACP3 (0.42) IDO1TDO2TSHRCYP1A2
SCHEMBL11091889 0.75 HSD17B10 (0.35) IDO1TDO2HSD17B10LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 IDO1 3181/4885TDO2 1351/4885HSD17B10 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.